| Literature DB >> 31850340 |
Iván Oseguera-López1, Sara Ruiz-Díaz2,3, Priscila Ramos-Ibeas3, Serafín Pérez-Cerezales3.
Abstract
Almost 50% of the infertility cases are due to male factors. Assisted reproductive technologies (ARTs) allow to overcome the incapacity of these patients' spermatozoa to fertilize the oocyte and produce a viable and healthy offspring, but the efficiency of the different techniques has still the potential to improve. According to the latest reports of the European Society of Human Reproduction and Embryology (ESHRE) and the Centers for Disease Control and Prevention of the United States (CDC), the percentages of deliveries per ART cycle in 2014 and 2016 were 21 and 22%, respectively. Among the reasons for this relatively low efficiency, the quality of the spermatozoa has been pointed out as critical, and the presence of high percentages of DNA-damaged spermatozoa in patients' ejaculates is possibly one of the main factors reducing the ARTs outcomes. Thus, one of the main challenges in reproductive medicine is to ensure the highest quality of the spermatozoa used in ARTs, and specifically, in terms of genetic integrity. The latest techniques for the preparation and selection of human spermatozoa are herein discussed focusing on those proven to improve one or several of the following parameters: sperm genetic integrity, fertilization capacity, embryo production, and in vitro survival, as well as pregnancy and delivery rates following in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). In addition, we discuss the potential of techniques developed in non-human mammals that could be further transferred to the clinic.Entities:
Keywords: ARTs; ICSI; IVF; sperm quality; sperm selection
Year: 2019 PMID: 31850340 PMCID: PMC6896825 DOI: 10.3389/fcell.2019.00298
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Methods for routine sperm preparation for ARTs. (A) Example of sperm selection by density gradient centrifugation (DGC): Semen is placed on top a gradient of colloid (e.g., silica particles coated with silane) prepared in a centrifuge tube and then subject to centrifugation. Subsequently, motile spermatozoa are recovered from the tube bottom containing the fraction with higher density of colloid. (B) Example of sperm selection by swim-up (SU): In a centrifuge tube, a medium free of cells (yellow in the figure) is placed on top of the seminal sample (green in the figure). The tube is then inclined 45° and incubated for about 1 h allowing motile spermatozoa to swim-up towards the medium free of cells where they are collected for downstream applications.
FIGURE 2Methods for sperm selection based on membrane characteristics. (A) Example of Annexin V magnetic activated cell sorting (AV-MACS): Apoptotic spermatozoa (red in the figure) are bound to magnetic nanoparticles coated with Annexin V and affinity to the externalized phosphatidylserine in this sperm population. Semen is then passed through a column with magnetos on the side, thus apoptotic spermatozoa are retained and non-apoptotic are washed out for downstream applications. (B) Example of method for sperm selection based on hyaluronic acid-binding. Spermatozoa are placed on a dish coated with hyaluronic acid (HA, orange in the figure). Matured spermatozoa bind to the surface due to their interaction with the HA. These spermatozoa can be then recovered for ICSI using a micromanipulation system. (C) Example of sperm selection by the Z-method developed by Ainsworth et al. (2005): Spermatozoa are placed in a well isolated from another adjacent well by a porous membrane and filled with a medium free of cells. An electric field is then applied with the anode in the well free of cells and the cathode in the well containing the sperm suspension. Due to the negative charge of the sperm membrane, spermatozoa migrate towards the compartment free of cells passing through the porous membrane. Spermatozoa can be then collected for downstream applications.
DNA fragmentation of spermatozoa selected by AV-MACS.
| Unsorted | 14.4 ± 13.2a | Donors (35) | |
| Annexin positive | 21 ± 13.6b | ||
| Annexin negative | 9.7 ± 10.6c | ||
| DGC | 13.5 ± 5.6 | Normozoospermic (60) | |
| DGC/AV-MACS | 9.9 ± 3.6*** | ||
| Unsorted | 29,72 ± 3.41a | Infertile, various etiologies (15) | |
| DGC | 21,27 ± 3.47b | ||
| AV-MACS | 21,72 ± 3.41b | ||
| DGC/AV-MACS | 17,63 ± 3.72c | ||
| AV-MACS/DGC | 15,27 ± 3.49c | ||
| Unsorted | 17.7 ± 1.6 | Fertile (10), infertile (26): terato- and asthenozoospermia | |
| MACS | 12.1 ± 1.7∗ | ||
| Unsorted | 3.48 ± 4.54a | Infertile, various etiologies (25) | |
| DGC/AV-MACS | 2.41 ± 2.72b | ||
| DGC/SU | 2.1 ± 2.75c | ||
| Unsorted | 12.43 ± 6.29 | Infertile, vaticocele (36) | |
| AV-MACS | 9.61 ± 5.62∗ | ||
| SU | 21.4 ± 16.6 | Normozoospermic (10) | |
| SU/AV-MACS | 15 ± 4.9 | ||
| DGC | 18.6 ± 5.8 | ||
| DGC/AV-MACS | 21 ± 6.4 | ||
| SU | 12 ± 16.6 | Oligozoospermic (10) | |
| SU/AV-MACS | 9.4 ± 9.9 | ||
| DGC | 10.6 ± 8.4 | ||
| DGC/AV-MACS | 8.4 ± 6.3 | ||
| Unsorted | 24 (9–26) | Normozoospermic (15) | |
| DGC | 10 (5–16) | ||
| DGC/AV-MACS | 6 (3–11) | ||
| AV-MACS/DGC | 4 (2–7) | ||
| AV-MACS | 8 (6–16) | ||
| Unsorted | 9.56 ± 3.39a | Asthenozoospermic (16) | |
| DGC | 5.25 ± 1.61b | ||
| DGC/AV-MACS | 2.75 ± 1.2c | ||
Reproductive outcomes of ARTs employing spermatozoa selected by AV-MACS.
| Fresh. oligoastheno- zoospermic | ND | DGC | 69.9 | 88.2 | 85 | ND | 36.49 | ND | |
| AV-MACS | 69.52 | 97.2∗ | 84.9 | 48.36∗ | |||||
| Cryopreserved | Donors | SU/AV-MACS | 75.3 (71.6–78.9) | ND | ND | 123 | 64.2 (55.4–72.1) | 48.4 (39.6–57.1) | |
| SU | 72.1 (68.6–75.7) | 114 | 71.1 (62.1–78.6) | 56.4 (47.3–65.5) | |||||
| Fresh. high DNA fragmentation | Donors | DGC | 76.5 | 89.1 | 41.1 | 146 | 45.5 | ND | |
| DGC/AV-MACS | 74.5 | 98.3 | 50.8 | 107 | 63.2 | ||||
| Fresh. infertile, at least two abnormal parameters | Donors | DGC | 74.78 + 3.41 | ND | ND | 33 | 24.24 | ND | |
| MACS + DGC | 76.13 + 4.38 | 22 | 54.54∗∗ | ||||||
| Fresh. teratozoospermic | Patients. women aged ≤ 30 years | DGC/SU | 70.6 | 100 | 56.5 | 4 | 50 | 50 | |
| DGC/SU/AV-MACS | 65.6 | 95.2 | 41.2 | 4 | 75 | 50 | |||
| Patients. women aged ≥ 31 years | DGC/SU | 79.8 | 97.5 | 41.1 | 5 | 20 | 20 | ||
| DGC/SU/AV-MACS | 69.5 | 97 | 41.4 | 12 | 16.7 | 16.7 | |||
DNA fragmentation of spermatozoa selected by hyaluronic acid.
| Unsorted | 32.87 ± 8.65 | Patients (77): Severe (13%), moderate (61%), and normospermic (26%) | SCD | |
| PICSI | 30.94 ± 8.7 | |||
| Unsorted | 16.5a | Patients (20): Normozoospermic (12) and oligozoospermic (8) | SCD | |
| SU | 11b | |||
| Microscopically selected | 11c | |||
| Sperm slow | 5.3d | |||
| Unsorted | 45 ± 1.9 | Patients (50) | AOF | |
| PICSI | 0.9 ± 1.9∗∗ | |||
| DGC | 26,8 | Donors (50) | TUNEL | |
| DGC/PICSI | 2.6 | |||
| DGC/IMSI | 1.7 | |||
| DGC | 33.2a | Patients (46) | AOF | |
| Microscopically selected | 17.9b | |||
| PICSI | 16.1b | |||
Reproductive outcomes of ARTs spermatozoa selected by hyaluronic acid.
| Patients: wide range of sperm quality | Patients. different conditions | 50 | HA coated dishes | 79.4 ± 26 | ND | ND | ND | 40 | ND | |
| PVP | 67.7 ± 23.5 | 55 | ||||||||
| Patients: oligozoospermic | Patients: average age of 37–38 years | 112 | HA solution | 91.6 | ND | ND | 125 | 24.8 | 23.2 | |
| 94 | PVP | 85.8 | 105 | 20.9 | 18 | |||||
| Patients | Patients: age ≤ 39 years | 293 | HA coated dishes | 93.4 | ND | ND | 326 | 32.8 | 16.3 | |
| 86 | PVP | 87.1 | 96 | 21.6 | 18.8 | |||||
| Patients: normozoospermic | Patients: ages ranged from 30 to 42 years | 18 | HA solution | 75.7 | 72.9 | 22.9 | ND | ND | ND | |
| PVP | 83 | 83 | 24 | |||||||
| Patients: motility ≥ 5%, total sperm number ≥ 1 × 106 | Patients: age ≤ 40 years | 50 | HA coated dishes | 82 | ND | ND | 49 | 42.9 | 18 | |
| 50 | HA solution | 82 | 50 | 40 | 15 | |||||
| Patients | Patients: age < 38 and other selection criteria | 71 | HA coated dishes | 64.7 | ND | ND | 177 | 35.2 | 12.4 | |
| 80 | PVP | 65.7 | 192 | 35 | 10.9 | |||||
| Patients | Patients: (age < 40 years) | 63 | HA coated dishes | ND | ND | ND | ND | 50.8∗ | ND | |
| 58 | PVP | 37.9 | ||||||||
| Patients | Patients (age < 40 years) | 102 | HA coated dishes | 55.7 | ND | ND | ND | 39.3∗∗ | 0.49∗∗∗ | |
| 42 | PVP | 52.8 | 26.6 | 0.27 | ||||||
| Patients: various male factors included | ND | 19 | HA coated dishes | 71.93 | 95.12 | ND | 19 | 42.1∗∗∗ | ND | |
| 37 | PVP | 64.14 | 95.27 | 37 | 16.21 | |||||
| Patients: able to produce freshly ejaculate (ages 18–55 years) | Patients: age (18–43) | 1387 | HA coated dishes | 66 | ND | ND | 1381 | 35.2 | 27.4 | |
| 1385 | PVP | 69 | 1371 | 35.7 | 25.2 | |||||
DNA fragmentation of spermatozoa selected by Zeta method.
| Unsorted | 19 ± 0.1 | Patients (8) | AOF | |
| Zeta | 11 ± 0.1∗ | |||
| Unsorted | 8 ± 2∗ | Donors (6) | TUNEL | |
| Zeta | 3 ± 2 | |||
| Unsorted | 49.65 ± 15.1a | Patients (60) | AOF | |
| DGC | 32.65 ± 14.38b | |||
| Zeta | 28.85 ± 15.83c | |||
| Unsorted | 15.83 ± 8.14a | Patients (55) | TUNEL | |
| DGC | 8.17 ± 4.23b | |||
| Zeta | 5.89 ± 3.92c | |||
| Unsorted | 50.43 ± 15.58a | Patients (51) | SCD | |
| DGC | 33.58 ± 16.24b | |||
| Zeta | 29.21 ± 14.95c | |||
| Unsorted | 32.87 ± 8.65a | Patients (77), 13, 61, and 26% (severe, moderate, and normospermic respectively) | SCD | |
| HA coated dish | 30.94 ± 8.7ab | |||
| Zeta | 18.19 ± 8.64b | |||
| Unsorted | 21.97 ± 3.84a | Patients (30) | TUNEL | |
| DGC | 17.47 ± 3.52b | |||
| DGC-Zeta | 6.98 ± 1.45c | |||
| Unsorted | 17.7 ± 1.6a | Fertile (10), infertile (26): terato- and asthenozoospermia | TUNEL | |
| MACS-DGC | 12.1 ± 1.7b | |||
| DGC-Zeta | 9.8 ± 1.2b | |||
FIGURE 3Intracytoplasmic morphologically selected sperm injection (IMSI). Spermatozoa are examined under a magnification system of 6300x in order to discriminate those spermatozoa lacking vacuoles (arrow) and showing normal morphology. These spermatozoa are collected with the micromanipulation system for their use in ICSI.
DNA fragmentation of spermatozoa selected by IMSI.
| Normal nucleus | 15.9//33.1 | Patients (30) | TUNEL//AOF | |
| Large vacuoles | 29.1∗∗∗//67.9∗∗∗ | |||
| ICSI | 16.2 ± 8.8 | Patients: ICSI (139), IMSI (116) | TUNEL | |
| IMSI | 16.4 ± 9.5 | |||
| Unsorted | 26.1 ± 1.5a | Infertile donors (8) (more than 13% of fragmented DNA spermatozoa) | TUNEL | |
| Motile 200x | 20.8 ± 2.7ab | |||
| Motile and normal Spermatozoa 200x | 18.7 ± 2.7ab | |||
| Motile and normal spermatozoa 6300x | 4.1 ± 1.1c | |||
| Morphometrically normal with anterior/posterior vacuoles 6300x | 15.9 ± 2.9b/22.5 ± 3.6ab | |||
| IMSI no vacuoles | 20.1//17.8 | Strict morphology index ≤ 4% (26) | AOF//TUNEL | |
| IMSI vacuoles | 22.6−35.2∗//18.2−25.4 | |||
| IMSI No vacuoles | 6.1//3.6 | Strict morphology index ≥ 14% (20) | AOF//TUNEL | |
| IMSI Vacuoles | 4.9–36.2∗//5.2–16.2∗ | |||
Reproductive outcomes of ARTs spermatozoa selected by IMSI.
| ≧3 millions of spermatozoa in the ejaculate, ≦1 million of motile after DGC, whatever sperm morphology | Younger than 39 years and FSH under of 9 UI/L | 458 | IMSI | 56 | ND | ND | ND | 31 | 27 | |
| ICSI | 63 | 33 | 30 | |||||||
| Oligo-astheno-teratozoospermia | Patients | 66 | ICSI | 65 ± 21.1 | ND | ND | 64 | 6.3 | ND | |
| IMSI | 67.7 ± 19.9 | 66 | 27.3 | |||||||
| At least one sperm pathology | Infertile Women | 42 | IMSI | 51.4 | 95.3 | ND | ND | 41.3∗ | 34.7∗∗ | |
| ICSI | 53.2 | 92 | 10.5 | 0 | ||||||
| Patients | Normo response (> 4 oocytes retrieved) | 324 | ICSI | 75.9 ± 18.9 | ND | 30.9 ± 28.1 | ND | 39,4 | ND | |
| IMSI | 72.3 ± 21.2 | 29.3 ± 25.7 | 34,1 | |||||||
| Poor response (< four oocytes retrieved) | 90 | ICSI | 79.8 ± 29.3 | ND | 9.8 ± 21.1 | ND | 11.8 | ND | ||
| IMSI | 53.9 ± 36.7 | 13.9 ± 33 | 22.2 | |||||||
| Couples with two previous ICSI failures | 216 | IMSI | 54 | ND | ND | 119 | 27 | 20 | ||
| ICSI | 61 | 86 | 28 | 19 | ||||||
| OAT/severe OAT (SOAT) or teratozoospermia | Patients | 57 | IMSI | 52∗∗ | ND | ND | ND | 68.5∗∗∗ | 62.4∗∗∗ | |
| ICSI | 30 | 30.2 | 0 | |||||||
| Mild to severe oligo, astheno, and/or teratozoospermia | Donors | 848 | IMSI | 82 | 70 | 42 | 511 | 63,79 | ||
| ICSI | 72 | 69 | 40 | 923 | 69,33 | |||||
FIGURE 4Methods for sperm selection based in guidance mechanisms. (A) Method of sperm selection by rheotaxis developed by Nagata et al. (2018). A flow (blue arrows) is created through a serial of microchannels towards a well were sperm sample is placed. In response to the flow the spermatozoa swim towards it passing through the microchannels and accumulating in a receptive well where they can be collected for downstream applications (red arrows indicate migration of the sperm). (B) Method of sperm selection by chemotaxis developed by Gatica et al. (2013): Two wells are connected by a 2 mm length per 2.5 mm diameter tube. One of the wells is filled with a medium containing the chemoattractant molecule in solution (colored in blue) and the other well is filled with the spermatozoa suspension. The chemoattractant diffuses through the connecting tube generating a gradient and the spermatozoa respond by migrating towards the higher concentration and accumulating in the initial well free of cells where they can be collected for downstream applications. (C) Method of sperm selection by thermotaxis developed by Pérez-Cerezales et al. (2018). Spermatozoa are placed on a drop of a medium connected by a capillary to a second drop free of cells. A temperature gradient is generated between both drops being the highest temperature at the place of the drop free of cells. Spermatozoa respond by thermotaxis migrating towards the warmer temperature and accumulating in the second drop where they can be collected for downstream applications.
DNA fragmentation of spermatozoa selected by microfluidic devices.
| Human | Control | 10.9 | Healthy donors (8) | SCSA | |
| Microfluidic radial 500 channels in parallel | 4.32/3.37/2.40 | ||||
| Human | Control | 27.7 ± 0a | Donors (10) normal, oligozoospermia, and asthenozoospermia | SCD | |
| SU | 8.3 ± 0.05b | ||||
| Sperm sorter qualis | 5.9 ± 0.04c | ||||
| Human | DGC-SU | 10.1 ± 8.5 | Donors (37) | SCSA | |
| Sperm sorter qualis | 0.8 ± 1.9∗ | ||||
| Bovine | Unsorted | 7.08 ± 1.06 | 7 | TUNEL | |
| Microfluid DMSS | 0.37 ± 0.15∗∗ | 12 | |||
| Human | Control | 15 (11–19)∗∗∗ | Samples (70) | SCD | |
| DGC-SU | 6 (3–11.5)∗∗∗ | ||||
| Fertile (Zymot) device | 0 (0–2.4) | ||||